Medifast (MED) Cash & Equivalents (2010 - 2026)

Medifast (MED) has 17 years of Cash & Equivalents data on file, last reported at $71.5 million in Q1 2026.

• Quarterly Cash & Equivalents fell 22.01% year-over-year to $71.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.5 million (down 22.01% YoY) and the FY2025 annual result came in at $89.3 million, down 1.79% from the prior year.
• Cash & Equivalents eased to $71.5 million in Q1 2026, from $89.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $147.4 million in Q2 2023 to a low of $61.1 million in Q2 2022.
• A 5-year average of $98.8 million and a median of $97.5 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 68.19% — and 2023, when it surged 141.37%.
• Tracing MED's Cash & Equivalents over 5 years: stood at $87.7 million in 2022, then gained by 7.7% to $94.4 million in 2023, then dropped by 3.72% to $90.9 million in 2024, then retreated by 1.79% to $89.3 million in 2025, then dropped by 19.9% to $71.5 million in 2026.
• The last three Cash & Equivalents figures came in at $71.5 million (Q1 2026), $89.3 million (Q4 2025), and $99.5 million (Q3 2025), per Business Quant data.